

 Rudolf-Wissell-Str. 28

 37079 Göttingen, Germany

 Phone:
 +49 551-50556-0

 Fax:
 +49 551-50556-384

 E-mail:
 sales@sysy.com

 Web:
 www.sysy.com

CD 11c

Cat.No. 375-0P; control peptide, 100 µg peptide (lyophilized)

Data Sheet

Reconstitution/ Storage	100 μg peptide, lyophilized. For reconstitution add 100 μl H₂O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C until use. Control peptides should also be stored at -20°C when still lyophilized!
Applications	WB: N/A IP: N/A ICC: N/A IHC: N/A IHC-P/FFPE: N/A
Immunogen	Synthetic peptide corresponding to AA 1159 to 1169 from mouse CD11c (UniProt Id: Q9QXH4)
Recommended dilution	Optimal concentrations should be determined by the end-user.
matching antibodies	375 003
Remarks	This control peptide consists of the synthetic peptide (aa 1159 - 1169 of mouse CD 11c) that has been used for immunization. It has been tested in preadsorption experiments and blocks efficiently and specifically the corresponding signal in Western blots. The amount of peptide needed for efficient blocking depends on the titer and on the affinity of the antibody to the antigen.

TO BE USED IN VITRO / FOR RESEARCH ONLY NOT TOXIC, NOT HAZARDOUS, NOT INFECTIOUS, NOT CONTAGIOUS

CD 11c or Integrin alpha-X (ITGAX) is a heterodimeric glycoprotein consisting of an α- and β-subunit and has seven repeating integrin domains. This transmembrane receptor type I plays a pivotal role in T cell killing and mediates intercellular adhesions during inflammation. Predominat expression levels have been found in dendritic cells, monocytes, macrophages, neutrophils and a small subset of B cells. Under pathological conditions, CD 11c is a marker for hairy cell leukemia, acute non-lymphocytic leukemias, and some chronic lymphocytic leukemias.

Selected General References

Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Osugi Y, Vuckovic S, Hart DN Blood (2002) 100(8): 2858-66.

Expression of the CD11c antigen in B-cell chronic lymphoproliferative disorders. Marotta G, Raspadori D, Sestigiani C, Scalia G, Bigazzi C, Lauria F Leukemia & lymphoma (2000) 37(1-2): 145-9.

CD11c integrin gene promoter activity during myeloid differentiation. Córbi AL, Lopéz-Rodríguez C Leukemia & lymphoma (1997) 25(5-6): 415-25.

Identification of Sp1-binding sites in the CD11c (p150,95 alpha) and CD11a (LFA-1 alpha) integrin subunit promoters and their involvement in the tissue-specific expression of CD11c. López-Rodríguez C, Chen HM, Tenen DG, Corbí AL European journal of immunology (1995) 25(12): 3496-503.